Area of research includes translational studies of cancer susceptibility that combine biomarker identification with screening of biomarkers in the population. The goal is understanding of carcinogenic mechanisms, identification of susceptible subgroups, early disease identification, and targeted therapy. Methods include proteomic biomarkers in serum; phenotypic measures of cancer susceptibility; and quantification of exposures and harm. Special interest in protein methyltransferases. Biomarkers are applied to head&neck and prostate cancer studies, which establish a growing human sample repository for translational research. Current research funded by NIH, ACS, and DOD.